July 2026 Research Update

This month added a clearer real-world picture that different gene-silencing medicines may not perform the same for ATTRv with polyneuropathy. In a Spanish multicenter report, people taking patisiran more often had stable or improved nerve exam scores over time than people taking inotersen, and they stayed on patisiran longer. This does not prove one drug caused better outcomes, but it strengthens the idea that treatment experiences can differ in routine care. [1]

The same report compared changes in a neuropathy impairment score over follow-up and found slower worsening with patisiran than with inotersen. Treatment stopping because of side effects was reported much more often with inotersen, while it was not seen with patisiran in this group. For patients, this helps set expectations that both nerve outcomes and day-to-day tolerability can vary depending on the medicine and the person. [1]

One practical addition was an early signal that certain baseline tests might help forecast treatment response. A measure related to sweat gland function in the hands and feet (electrochemical skin conductance) stood out as the strongest predictor among the measured markers, and one nerve signal measure (CMAP) also differed across response groups. This is still early and was based on one retrospective dataset, but it points toward more personalized monitoring in future research. [1]

For people living with ATTRv-related nerve symptoms, this month mainly adds understanding of what has been seen in routine practice rather than introducing new trial results. The Spanish experience suggests that people on patisiran, as a group, had more favorable nerve score trajectories and fewer treatment stops than people on inotersen, but the study cannot fully separate treatment effects from differences in who received each drug. The potential role of a simple skin-and-sweat measurement as a predictor is not ready for everyday decision-making, but it helps clarify what future studies may test to better match treatments and follow-up to individual patients. [1]

This month reinforced a simple message: earlier diagnosis matters, but access and follow-up still vary widely by country and by disease features. An international guideline and a Balkan regional expert report both described TTR stabilizers and gene silencers as core disease-modifying options, while noting that eligibility and reimbursement differ across settings. Together, these papers make the health-system side of ATTRv more visible: getting to the right test and the right medicine can depend on where someone lives. [2] [3]

The international guideline emphasized that disease-modifying therapies are expected to work best before significant organ damage has occurred. It also highlighted an important gap: current treatments have limited impact on central nervous system and eye involvement, and there is an urgent need for treatments that address those problems. For patients, this helps explain why symptoms affecting vision or the brain may not improve as much as nerve or heart-related issues with today’s options. [2]

The Balkan expert report described how care pathways can look very different even within one region. Bulgaria was described as using systematic family screening and rapid genetic testing with high early-diagnosis rates, while nearby countries reported more variable access and delays related to awareness and reimbursement. It also described multidisciplinary follow-up and the use of different tests to track nerve and autonomic symptoms, showing how monitoring can be structured when resources allow. [3]

For patients and caregivers, these papers do not add new patient-by-patient outcome data, but they help clarify why experiences differ across clinics and countries. They support the idea that genetic testing and family screening can shorten the time to diagnosis, and they explain that access to stabilizers and gene silencers may depend on local systems rather than medical need alone. They also make clear that eye and brain involvement remains a major unmet need, so progress there may depend on future treatments and studies. [2] [3]

This month added evidence that ATTRv can involve the brain coverings and the musculoskeletal system in ways that may be missed if the focus stays only on nerves and heart. In a V30M group, a particular MRI finding became more common and more extensive with longer disease duration, suggesting it could be a marker of central nervous system involvement over time. Separately, a single patient report showed amyloid deposits in knee synovial tissue during joint surgery, showing one way ATTRv can present with prominent joint and tendon problems. [4] [5]

In the MRI study of 44 people with the V30M mutation, about 3 in 10 had leptomeningeal enhancement, and those patients had longer disease duration than those without it. The authors described a pattern that could start as small, surface areas and become more diffuse, often near the back of the brain, while tiny brain bleeds did not track with disease duration in the same way. For patients, the main point is that some brain-related changes may develop gradually and might be detectable on imaging in certain subtypes. [4]

The case report described a man whose ATTRv (Tyr98Phe) showed strong musculoskeletal involvement, including carpal tunnel and joint problems, and amyloid was confirmed in synovial tissue from knee arthroplasty. Genetic testing helped connect the joint findings to hereditary ATTR, and the report also noted mild nerve involvement and largely normal heart testing at that time. While a single case cannot predict what will happen for others, it expands the picture of how ATTRv can appear in everyday care. [5]

For patients, this information mainly matters as added understanding rather than a change in current care. The MRI findings are from a retrospective study in one mutation group, so it is not yet clear how often this applies to other ATTRv variants or whether it should influence monitoring. The joint-tissue case report is a reminder that ATTRv can sometimes be recognized through non-nerve, non-heart clues, but it remains an individual example rather than a general rule. Together, these studies help clarify that ATTRv can affect multiple body systems and that research is still working out the best ways to detect and track less common forms of involvement. [4] [5]